Osteoprotegerin, fibroblast growth factor 23, and vitamin D3 levels in male patients with hypogonadism

Hormone and Metabolic Research

Volumn 46, Issue 13, 2014, Pages 955-958

  Meric, C ^a   Sonmez, A ^a   Aydogdu, A ^a   Tapan, S ^a   Haymana, C ^a   Basaran, Y ^a   Baskoy, K ^a   Sertoglu, E ^a   Taslipinar, A ^a   Bolu, E ^a   Azal, O ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

asymmetric dimethyl arginine; fibroblast growth factor 23; hypogonadism; osteoprotegerin; vitamin D3

Indexed keywords

COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; INSULIN; N(G),N(G) DIMETHYLARGININE; OSTEOPROTEGERIN; TESTOSTERONE; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; DEMOGRAPHY; HYPOGONADISM; YOUNG ADULT;

CASE-CONTROL STUDIES; CHOLECALCIFEROL; DEMOGRAPHY; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGONADISM; MALE; OSTEOPROTEGERIN; YOUNG ADULT;

EID: 84915753680     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1387789     Document Type: Article

References (43)

1. Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J., Swerdloff R. S., Montori V. M. Task Force, Endocrine Society Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab: 2010; 95 2536 2559
2. Ferlin A., Schipilliti M., Di Mambro A., Vinanzi C., Foresta C. Osteoporosis in Klinefelter's syndrome. Mol Hum Reprod: 2010; 16 402 410
3. Francis R. M., Peacock M., Aaron J. E., Selby P. L., Taylor G. A., Thompson J., Marshall D. H., Horsman A. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone: 1986; 7 261 268
4. Dupree K., Dobs A. Osteopenia and male hypogonadism. Rev Urol: 2004; 6 06 S30 S34
5. Jackson J. A., Kleerekoper M., Parfitt A. M., Rao D. S., Villanueva A. R., Frame B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab: 1987; 65 53 58
6. Laitinen E. M., Hero M., Vaaralahti K., Tommiska J., Raivio T. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. Int J Androl: 2012; 35 534 540
7. Bojesen A., Birkebaek N., Kristensen K., Heickendorff L., Mosekilde L., Christiansen J. S., Gravholt C. H. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int: 2011; 22 1441 1450
8. Kupelian V., Page S. T., Araujo A. B., Travison T. G., Bremner W. J., McKinlay J. B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab: 2006; 91 843 850
9. Stellato R. K., Feldman H. A., Hamdy O., Horton E. S., McKinlay J. B. Testosterone sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care: 2000; 23 490 494
10. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T. P., Valkonen V. P., Salonen R., Salonen J. T. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes mellitus in middle-aged men. Diabetes Care: 2004; 27 1036 1041
11. Laughlin G. A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab: 2008; 93 68 75
12. Sonmez A., Haymana C., Bolu E., Aydogdu A., Tapan S., Serdar M., Altun B., Barcin C., Taslipinar A., Meric C., Uckaya G., Kutlu M. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Eur J Endocrinol: 2011; 164 759 764
13. Cersosimo E., DeFronzo R. A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev: 2006; 22 423 436
14. Gast K. B., Tjeerdema N., Stijnen T., Smit J. W., Dekkers O. M. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One: 2012; 7 e52036
15. Böger R. H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res: 2009; 60 481 487
16. Cakir E., Ozcan O., Yaman H., Akgul E. O., Bilgi C., Erbil M. K., Yesilova Z. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. J Clin Endocrinol Metab: 2005; 90 1651 1654
17. Raggi P., Giachelli C., Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med: 2007; 4 26 33
18. Larsson T. E. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant: 2010; 25 1376 1381
19. Zoccali C., Yilmaz M. I., Mallamaci F. FGF23: a mature renal and cardiovascular risk factor? Blood Purif: 2013; 36 52 57
20. Yilmaz M. I., Sonmez A., Saglam M., Yaman H., Kilic S., Turker T., Unal H. U., Gok M., Cetinkaya H., Eyileten T., Oguz Y., Caglar K., Vural A., Mallamaci F., Zoccali C. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol: 2013; 37 126 134
21. Tintut Y., Alfonso Z., Saini T., Radcliff K., Watson K., Bostrom K., Demer L. L. Multilineage potential of cells from the artery wall. Circulation: 2003; 108 2505 2510
22. Hofbauer L. C. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol: 1999; 141 195 210
23. Browner W. S., Lui L. Y., Cummings S. R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab: 2001; 86 631 637
24. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation: 2004; 109 2175 2180
25. Venuraju S. M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity. J Am Coll Cardiol: 2010; 55 2049 2061
26. Holick M. F. Vitamin D deficiency. N Engl J Med: 2007; 357 266 281
27. London G. M., Guérin A. P., Verbeke F. H., Pannier B., Boutouyrie P., Marchais S. J., Mëtivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25- hydroxyvitamin D deficiency. J Am Soc Nephrol: 2007; 18 613 620
28. Pittas A. G., Lau J., Hu F. B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab: 2007; 92 2017 2029
29. Forouhi NG, Luan J., Cooper A., Boucher B. J., Wareham N. J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes: 2008; 57 2619 2625
30. Burnett-Bowie S. M., Mendoza N., Leder B. Z. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone: 2007; 40 913 918
31. Pepene C. E., Cri͆an N., Coman I. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism. Clin Invest Med: 2011; 34 E232
32. Lee D. M., Tajar A., Pye S. R., Boonen S., Vanderschueren D., Bouillon R., WO'Neill T., Bartfai G. F., Casanueva F., Finn J. D., Forti G., Giwercman A., Han S. T., Huhtaniemi I. T., Kula K., Lean EJ M., Pendleton N., Punab M., Wu CW F. The EMAS study group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol: 2012; 166 77 85
33. Wehr E., Pilz S., OBoehm B., Marz W., Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clinical Endocrinol: 2010; 73 243 248
34. Lichtenstein M. J., Yarnell J. W., Elwood P. C., Beswick A. D., Sweetnam P. M., Marks V., Teale D., Riad-Fahmy D. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol: 1987; 126 647 657
35. Laughlin G. A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab: 2008; 93 68 75
36. Khaw K. T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation: 2007; 116 2694 2701
37. Meinitzer A., Kielstein J. T., Pilz S., Drechsler C., Ritz E., Boehm B. O., Winkelmann B. R., März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem: 2011; 57 112 121
38. Chan N. N., Chan J. C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia: 2002; 45 1609 1616
39. Lavie C. J., Lee J. H., Milani R. V. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol: 2011; 58 1547 1556
40. Ergür A. T., Berberoʇlu M., Atasay B., Şiklar Z., Bilir P., Arsan S., Söylemez F., Öcal G. Vitamin D Deficiency in Turkish Mothers and Their Neonates and in Women of Reproductive Age. J Clin Res Ped Endo: 2009; 1 266 269
41. Meer I. M., Middelkoop BJ C., Boeke AJ P., Lips P. Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos Int: 2011; 22 1009 1021
42. Akpinar P., Icagasioglu A. The releation between vitamin D and quality of life. Turkish Journal of Osteoporosis: 2012; 18 13 18
43. Atli T., Gullu S., Uysal A. R., Erdogan G. The prevalence of Vitamin D deficiency and effects of ultraviolet light on Vitamin D levels in elderly Turkish population. Arch Gerontol Geriatr: 2005; 40 53 60.